Universitair Medisch Centrum Groningen

Running trials

• Not yet recruiting

  Addition of ritonavir to ibrutinib treatment in patients with chronic leukemia and certain types of lymphoma

  2026-526101-15-00· Phase 2· Source

• Not yet recruiting

  To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)

  NCT07116473· Phase 3· Source

• Not yet recruiting

  A Multicenter, Phase 2/3, Dose Range Finding Study to Evaluate the Efficacy and Safety of Atumelnant in Adults with ACTH-Dependent Cushing’s Syndrome (ADCS) Including an Open-Label Extension for Long-Term Assessment. (EQUILIBRIUM-ADCS)

  2025-522648-42-01· Phase 2/3· Source

• Recruiting

  Evaluation of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)

  2025-523288-39-00· Phase 2· Source

• Recruiting

  A clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease

  2026-525197-19-00· Phase 2· Source

• Recruiting

  Albuminuria Reduction Trial and Investigation with Survodutide Treatment in CKD (ARTIST-CKD)

  2025-525068-13-00· Phase 2· Source

• Recruiting

  A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)

  NCT07843940· Phase 1/2· Source

• Recruiting

  A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML

  NCT07751991· Phase 1· Source

• Recruiting

  A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

  2026-526654-14-01· Phase 3· Source

• Not yet recruiting

  A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies

  NCT07719348· Phase 1/2· Source

• Not yet recruiting

  A Phase 2, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of CRD-4730 in patients with heart failure with reduced ejection fraction (HFREF) (CALIBRATE-HF)

  2025-525033-31-00· Phase 2· Source

• Recruiting

  A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

  NCT07665450· Phase 3· Source

• Not yet recruiting

  In Vivo Fluorescence Molecular Bronchoscopy of Durvalumab-680LT in Patients With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) After Chemoradiotherapy

  NCT07653438· Phase 2· Source

• Not yet recruiting

  Endoscopic (EID) Versus Surgical (TAMIS) Local Excision for Early Stage Rectal Cancer

  NCT07846046· Source

• Recruiting

  A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC

  NCT07807163· Phase 2· Source

• Recruiting

  A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation

  NCT07625215· Phase 2· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

  NCT07564141· Phase 3· Source

• Recruiting

  A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease

  NCT07737743· Phase 2· Source

• Not yet recruiting

  Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy

  NCT06809946· Phase 2· Source

• Recruiting

  Tarlatamab for SCLC Brain Metastases

  NCT07402343· Phase 2· Source

• Not yet recruiting

  A study investigating the safety and efficacy of academically-produced CAR T cells compared with standard treatment for patients with multiple myeloma whose disease has returned or not responded to previous treatments.

  2025-524876-43-00· Phase 3· Source

• Recruiting

  Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)

  2023-505575-69-01· Phase 3· Source

• Recruiting

  Dietary Fiber to Induce Gut Microbiota-mediated Response to Immunotherapy in Melanoma.

  NCT07686835· Phase 2· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Source

• Recruiting

  Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden

  NCT07621809· Phase 3· Source

• Recruiting

  Methotrexate in paediatric and adolescent Crohn’s disease: an observational study

  2025-524129-42-00· Phase 4· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Source

• Recruiting

  [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

  NCT07702292· Phase 2· Source

• Recruiting

  A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

  NCT07554339· Phase 3· Source

• Recruiting

  PROTECx - Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer

  2025-522883-34-00· Phase 4· Source

• Not yet recruiting

  CANagliflozin In DIALysis Patients

  NCT07527390· Phase 4· Source

• Not yet recruiting

  Development of Fluorescent Lectin Tracers With Dedicated Technology for in Vivo Detection of Esophageal Dysplasia in Barrett Patients

  NCT07643727· Phase 1· Source

• Not yet recruiting

  HOVON 168:Study on epcoritamab in frail patients with diffuse large B-Cell lymphoma (DLBCL) who have not been treated before

  2025-524230-25-00· Phase 2· Source

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Source

• Recruiting

  A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

  NCT07513376· Phase 3· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

  NCT07416604· Phase 3· Source

• Recruiting

  Neoadjuvant gemcitabine and cisplatin in combination with perioperative pembrolizumab versus upfront surgery for patients with primary resectable and borderline resectable perihilar and distal cholangiocarcinoma (NEODISCO): A Multicentre Phase 2B/3 Randomised Controlled Trial

  2024-516898-72-00· Phase 2/3· Source

• Not yet recruiting

  Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy

  NCT07486687· Phase 3· Source

• Recruiting

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  NCT07361497· Phase 3· Source

• Recruiting

  Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  NCT07223814· Phase 3· Source

• Recruiting

  method VALIDation and evaluation of non-radioactive methods to measure Glomerular Filtration Rate

  NCT06259422· Phase 4· Source

• Recruiting

  First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)

  NCT07384715· Phase 1· Source

• Recruiting

  A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07258511· Phase 3· Source

• Recruiting

  Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

  NCT07431281· Phase 3· Source

• Recruiting

  IMCISION: Towards organ preservation and cure via ultra-short immunotherapy in advanced oral cancer. The IMCISION II trial, an investigator-initiated multicentre randomised phase 3 trial

  2025-522500-24-00· Phase 3· Source

• Recruiting

  Evaluating PD-1/PD-L1 in rectal cancer by quantitative fluorescence molecular endoscopy.

  NCT06304597· Phase 1· Source

• Recruiting

  A study to investigate the efficacy, safety, tolerability and pharmacokinetics of PKN605 in participants with atrial fibrillation

  2025-520518-79-00· Phase 2· Source

• Recruiting

  Pilot Study on Subcutaneously Administered Immunotherapy for the Treatment of Cervical Cancer

  2025-521771-31-00· Phase 1· Source

• Recruiting

  A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

  NCT07063745· Phase 2/3· Source

• Recruiting

  STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease

  NCT07280585· Phase 3· Source

Showing 50 of 252.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer23 recruiting
• Multiple myeloma13 recruiting
• Childhood cancers11 recruiting
• Colorectal cancer10 recruiting
• Gastric and oesophageal cancer9 recruiting
• Head and neck cancer7 recruiting
• Liver and biliary tract cancer7 recruiting
• Ovarian cancer7 recruiting
• Prostate cancer7 recruiting
• Acute myeloid leukaemia6 recruiting
• Amyloidosis6 recruiting
• Crohn's disease6 recruiting
• Heart failure6 recruiting
• Melanoma6 recruiting
• Cervical cancer5 recruiting
• Chronic kidney disease5 recruiting
• Pancreatic cancer5 recruiting
• Chronic lymphocytic leukaemia4 recruiting
• Endometrial cancer4 recruiting
• High blood pressure4 recruiting
• Atrial fibrillation3 recruiting
• Diffuse large B-cell lymphoma3 recruiting
• Myelodysplastic syndromes3 recruiting
• Obesity3 recruiting
• Parkinson disease3 recruiting
• Sarcoma3 recruiting
• Sjögren's disease3 recruiting
• Aortic stenosis2 recruiting
• Bladder cancer2 recruiting
• COPD2 recruiting
• Coronary artery disease2 recruiting
• Depression2 recruiting
• Follicular lymphoma2 recruiting
• Haemophilia2 recruiting
• Hodgkin lymphoma2 recruiting
• Lupus (SLE)2 recruiting
• Mantle cell lymphoma2 recruiting
• Stroke2 recruiting
• Systemic sclerosis (scleroderma)2 recruiting
• ALS (motor neurone disease)1 recruiting
• Alzheimer disease1 recruiting
• ANCA-associated vasculitis1 recruiting
• Barrett's oesophagus1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Cushing's syndrome1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Dilated cardiomyopathy1 recruiting
• Hidradenitis suppurativa1 recruiting
• Hypothyroidism1 recruiting
• Immune thrombocytopenia (ITP)1 recruiting
• Liver cirrhosis1 recruiting
• Meningioma1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple sclerosis1 recruiting
• Multiple system atrophy1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Neuroblastoma1 recruiting
• Neuroendocrine tumours1 recruiting
• Peripheral artery disease1 recruiting
• Polycystic kidney disease1 recruiting
• Polycystic ovary syndrome1 recruiting
• Psoriasis1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Rheumatoid arthritis1 recruiting
• Triple-negative breast cancer1 recruiting
• Type 2 diabetes1 recruiting
• Ulcerative colitis1 recruiting
• Vitiligo1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Not yet recruiting

  The MAB Trial: A Study of Tozorakimab to Reduce Lung Inflammation and Promote Lung Healing in People with COPD.

  2025-522359-24-00· Phase 2· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

  NCT07221357· Phase 2/3· Source

• Active, not recruiting

  Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

  NCT07161037· Phase 2· Source

• Completed

  SPECT/CT imaging of FPI-2505 in patients with solid tumours; a phase 0 molecular imaging basket trial (SCOPE-study).

  2025-521235-37-00· Phase 1· Source

• Recruiting

  Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

  NCT06966401· Phase 3· Source

• Completed

  A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY)

  NCT06684847· Phase 3· Source

• Completed

  A first-in-human study to determine the safety and tolerability of different doses of GEH200520 Injection and GEH200521 (18F) Injection and their uses in positron emission tomography imaging for patients with cancer

  2024-515218-42-00· Phase 1· Source

• Completed

  GENPAD

  NCT04619927· Phase 4· Source

• Recruiting

  PET-imaging of Two Vartumabs in Patients With Solid Tumors

  NCT06645808· Early phase 1· Source

• Completed

  Optical PD-L1 imaging using Quantitative Fluorescence Endoscopy in locally advanced esophageal cancer using durvalumab-680LT: a phase I multicenter feasibility and safety study

  2024-517258-85-00· Phase 1· Source

• Completed

  A Patient guided dose reduction strategy of tyrosine kinase inhibitors in chronic myeloid leukaemia: RODEO study

  2024-516511-24-00· Phase 4· Source

• Completed

  DECISION; Digoxin Evaluation in Chronic heart failure: Investigational Study In Outpatients in the Netherlands

  2023-509898-23-00· Phase 4· Source

• Completed

  A Phase 2 Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction

  2023-508736-62-00· Phase 2· Source

• Active, not recruiting

  Iptacopan in Patients With ANCA Associated Vasculitis

  NCT06388941· Phase 2· Source

• Completed

  Open-label Extension of Vericiguat in Pediatric Participants with Heart Failure due to Left Ventricular Systolic Dysfunction

  2023-506210-40-00· Phase 3· Source

• Active, not recruiting

  Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.

  NCT06359002· Phase 1· Source

• Completed

  A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

  NCT06238817· Phase 3· Source

• Completed

  A proof of concept and dose-finding study of XXB750 in patients with heart failure

  2023-504678-39-00· Phase 2· Source

• Completed

  A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Selnoflast in Participants with Moderate to Severe Asthma

  2023-504304-29-00· Phase 1· Source

• Completed

  Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)

  NCT06215586· Phase 2· Source

• Active, not recruiting

  A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

  NCT06212999· Phase 3· Source

• Active, not recruiting

  A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

  NCT06140836· Phase 3· Source

• Completed

  A first-in-human trial of safety and efficacy of GEN3017 in subjects with Hodgkin lymphoma or non-Hodgkin lymphoma

  NCT06018129· Phase 1/2· Source

• Completed

  STRIDER: A phase II Study evaluaTing intRacranial effIcacy of JDQ443 in patiEnts with KRAS G12C+ NSCLC and bRain metastases

  2023-505721-13-00· Phase 2· Source

• Completed

  A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

  NCT06066528· Phase 3· Source

• Completed

  A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

  NCT06066515· Phase 3· Source

• Completed

  Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).

  NCT05742802· Phase 3· Source

• Completed

  A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05724199· Phase 3· Source

• Completed

  A trial in patients with blood cancer and lymphatic system cancer looking at finding the optimal dose of BMF-219

  NCT05153330· Phase 1· Source

• Completed

  Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION)

  2023-508528-36-00· Phase 3· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Source

• Active, not recruiting

  Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

  NCT05502237· Phase 3· Source

• Completed

  ANISE-II; ANIfrolumab treatment for 24 weeks in patients with primary Sjögren’s syndrome – Efficacy and safety assessment in a randomized, double-blind, placebo-controlled phase-IIa proof-of-concept trial

  NCT05383677· Phase 2· Source

• Terminated

  A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05325866· Phase 1/2· Source

• Active, not recruiting

  Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

  NCT05263934· Phase 3· Source

• Terminated

  Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

  NCT05079230· Phase 3· Source

• Completed

  First-in-human study of SAR443579 infusion in male and female children and adult participants with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), high risk-myelodysplasia (HR-MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN)

  2023-508357-58-00· Phase 1/2· Source

• Enrolling by invitation

  A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)

  NCT05352919· Phase 3· Source

• Completed

  Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD

  NCT05326412· Phase 2· Source

• Active, not recruiting

  PD-L1 PET-imaging During CAR T-cell Therapy

  NCT05404048· Phase 2· Source

• Active, not recruiting

  New Clinical End-points in patients with primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients

  NCT05113004· Phase 2· Source

• Completed

  Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts

  NCT05369975· Phase 3· Source

• Completed

  A study to test long-term safety of Iclepertin in people with schizophrenia who took part in a previous CONNEX study

  2024-511560-93-00· Phase 3· Source

• Active, not recruiting

  A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

  NCT05196035· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma

  NCT04980222· Phase 2· Source

• Active, not recruiting

  A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis

  NCT05250973· Phase 2· Source

• Completed

  Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma

  NCT05251259· Phase 2· Source

• Completed

  Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

  NCT05166889· Phase 3· Source

• Completed

  Prediction of ECT treatment response and reduction of Cognitive Side-effects using EEG and Rivastigmine

  2024-518047-37-01· Phase 4· Source

• Completed

  Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)

  NCT04846881· Phase 3· Source

Showing 50 of 87.